What is Zacks Research’s Estimate for Surmodics Q2 Earnings?

Surmodics, Inc. (NASDAQ:SRDX) – Zacks Research upped their Q2 2025 earnings estimates for shares of Surmodics in a research note issued on Wednesday, February 19th. Zacks Research analyst D. Dey now anticipates that the company will earn ($0.04) per share for the quarter, up from their prior forecast of ($0.05). The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics’ Q4 2026 earnings at $0.18 EPS, FY2026 earnings at $0.78 EPS and FY2027 earnings at $0.87 EPS.

SRDX has been the topic of a number of other reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research report on Thursday, January 30th. StockNews.com started coverage on shares of Surmodics in a research note on Monday, February 3rd. They set a “hold” rating on the stock. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $50.00.

Surmodics Price Performance

SRDX stock opened at $34.85 on Monday. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26. Surmodics has a 12-month low of $25.17 and a 12-month high of $42.44. The company has a market cap of $498.36 million, a PE ratio of -34.50 and a beta of 1.20. The stock has a 50-day moving average price of $37.02 and a two-hundred day moving average price of $38.34.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings results on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.04. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%.

Hedge Funds Weigh In On Surmodics

Several large investors have recently modified their holdings of the stock. Olympiad Research LP acquired a new stake in shares of Surmodics during the 3rd quarter valued at approximately $1,884,000. Principal Financial Group Inc. acquired a new stake in shares of Surmodics during the third quarter worth $1,190,000. Wolverine Asset Management LLC lifted its position in shares of Surmodics by 6.9% in the 3rd quarter. Wolverine Asset Management LLC now owns 27,766 shares of the company’s stock worth $1,077,000 after buying an additional 1,800 shares during the last quarter. Quest Partners LLC boosted its holdings in shares of Surmodics by 107,100.0% in the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after buying an additional 1,071 shares during the period. Finally, Phocas Financial Corp. bought a new stake in shares of Surmodics during the 3rd quarter valued at about $3,430,000. Institutional investors own 96.63% of the company’s stock.

Insider Buying and Selling at Surmodics

In other news, CFO Timothy J. Arens sold 7,009 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $39.44, for a total value of $276,434.96. Following the completion of the sale, the chief financial officer now owns 70,350 shares of the company’s stock, valued at approximately $2,774,604. The trade was a 9.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.90% of the stock is currently owned by corporate insiders.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).